c-Kit

Proto-oncogene c-KIT is the gene encoding the receptor tyrosine kinase protein known as tyrosine-protein kinase KIT, CD117 (cluster of differentiation 117) or mast/stem cell growth factor receptor (SCFR). Multiple transcript variants encoding different isoforms have been found for this gene.KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT is a receptor tyrosine kinase type III, which binds to stem cell factor (a substance that causes certain types of cells to grow), also known as "steel factor" or "c-kit ligand".

Cat. No.	Product name	CAS No.	Purity
T7861	Flumatinib mesylate	895519-91-2	99.82%
T7861	Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
T60976	Bezuclastinib	1616385-51-3	99.81%
T60976	Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.
T0520	Lenvatinib	417716-92-8	99.8000%
T0520	Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib h...
T6289	Dovitinib	405169-16-6	99.78%
T6289	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) an...
T2500	Cediranib	288383-20-0	99.78%
T2500	Cediranib (AZD2171) (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (I...
T79851	Labuxtinib	1426449-01-5	99.77%
T79851	Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].
T2624	OSI-930	728033-96-3	99.76%
T2624	OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
T2288L	Motesanib Diphosphate	857876-30-3	99.76%
T2288L	Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activi...
T1667	Tandutinib	387867-13-2	99.74%
T1667	Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus...
T4349	Sitravatinib	1123837-84-2	99.74%
T4349	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
T2372	Ponatinib	943319-70-8	99.74%
T2372	Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively)...
T1621	Imatinib Mesylate	220127-57-1	99.73%
T1621	Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, re...
T2446	KI8751	228559-41-9	99.73%
T2446	KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
T8482	Ripretinib	1442472-39-0	99.72%
T8482	Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.
T4409	Gilteritinib	1254053-43-4	99.72%
T4409	Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectivel...
T7945	SU14813	627908-92-3	99.72%
T7945	SU14813 is a multi-receptor tyrosine kinase inhibitor with potent antiangiogenesis and antitumor activity (IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ an...
T6930	Pazopanib Hydrochloride	635702-64-6	99.69%
T6930	Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM...
T6711	Tyrphostin AG1296	146535-11-7	99.68%
T6711	Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
T2115	Pexidartinib	1029044-16-3	99.66%
T2115	Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antin...
T0093L	Sorafenib	284461-73-0	99.61%
T0093L	Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/...